Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00461006 · ClinicalTrials.gov registry record · Phase 2
A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
NCT00461006 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 176 participants.
The verdict
NCT00461006, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
Study Summary
This 2 arm study will compare the effects of aleglitazar and Actos, added to preexisting oral antihyperglycemic therapy and/or diet and exercise, on renal function in patients with type 2 diabetes, and normal or mildly impaired renal function. Eligible patients will be randomized to receive either aleglitazar 0.6mg p.o. or Actos 45mg p.o. daily. Renal function and efficacy parameters will be assessed at intervals during the treatment period. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.
Interventions
- DRUG Actos
- DRUG aleglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00461006
The ClinicalTrials.gov registry entry for NCT00461006 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Actos is the first listed.
NCT00461006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00461006 about?
NCT00461006 is a clinical study titled "A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.". This 2 arm study will compare the effects of aleglitazar and Actos, added to preexisting oral antihyperglycemic therapy and/or diet and exercise, on renal function in patients with type 2 diabetes, and normal or mildly impaired renal function. Eligible patients will be randomized to receive either a...
What is the current status of trial NCT00461006?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2007-06. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00461006?
The interventions under investigation include: Actos (DRUG), aleglitazar (DRUG).
Who is sponsoring clinical trial NCT00461006?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.